SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

VDRM RSS Feed
Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, trop, Clonefan, GreenBrickRoad, Neptune, Tradingtrader01
Search This Board: 
Last Post: 3/29/2017 8:33:06 AM - Followers: 499 - Board type: Free - Posts Today: 16

VDRM

ViaDerma, Inc.

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

 

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

Contact Details

ViaDerma's global headquarters is located at
8950 W. Olympic Blvd, Suite 576, Beverly Hills, CA 90211.

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

Phone: 310.871.3996

Headlines Get Headlines for:

Tuesday, August 5, 2014

Tuesday, June 10, 2014

Older Headlines - Most Recent Headlines

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 

Authorized Shares: 150,000,000 a/o April 4, 2016

Outstanding Shares: 125,042,787 a/o April 4, 2016

Float: 51,061,509 a/o March 31, 2016

Par Value    0.001

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

1) EXTREMELY OVERSOLD and unknown 
2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 
4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION!
6) WON AWARD FOR THEIR DRUG
7) STRONG HANDS HOLDING 11 million shares out of the TINY 18 million float.
8) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
9) THEY HAVE A PATENT which big boys have to be eyeing.

VDRM IS A HIDDEN GOLDMINE

THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HUGE:
 

VDRM ENTERS MMJ PLAYING FIELD

LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.


 

THE SECTION BELOW IS MANAGED BY MODERATOR NEPTUNE - LAST UPDATE 03.21.17
Text in blue font contains hyperlinks to detailed information.
 

Authorized  400,000,000   -   Issued & Outstanding  321,232,603   -   Restricted  57,975,478    -   Unrestricted  263,257,125

Confirmed by Transfer Agent March 07, 2017
Clear Trust LLC 813-235-4490

 

VIADERMA REGISTRATION     -     OTC PINK - UNAUDITED     -     VIADERMA II REGISTRATION

  

ViaDerma, Inc. is a specialty pharmaceutical company founded in 2014 by Dr. Chris Ayo Otiko, a Podiatrist.  Their current lead product is an FDA-registered
topical antibiotic called Viabecline that the Company manufactures and distributes under a
non-exclusive licensing and distribution agreement with Dr. Howard Phillips
of
the
Phillips Company, the world's only FDA-registered drug manufacturer that operates as a not-for-profit pharmaceutical research company.


Phillips transfers their technology and brand names to any company that can produce their new drugs in high volume, at low cost, and "take it to the people." 

Mr. Phillips has confirmed that ViaDerma has both a distributor's agreement for  Phillips-manufactured products; and a manufacturing
license for one product -- Diabecline or Viabecline.
National Library of Medicine Label Information is linked to Medication Name.
Ingredients are noted below for ease of comparison. Viabecline has two extra ingredients.

 
DIABECLINE VIABECLINE
Active
Ingredients
Tetracycline Hydrochloride 30 mg Active
Ingredients
Tetracycline Hydrochloride 30 mg
Inactive
Ingredients

Ascorbic Acid, Chlorhexidine Gluconate,
Cholecalciferol, Dimethyl Sulfoxide, Dipropylene Glycol,
Glucono Delta Lactone, Glycerin,

Hydroxethylc-Cellulose, Magnesium Stearate, Methylparaben,
Sodium Hydroxide, Sorbic Acid, Steric Acid, Water.
Inactive
Ingredients
Acetic Acid
Ascorbic Acid, Chlorhexidine Gluconate,
Cholecalciferol, Dimethyl Sulfoxide, Dipropylene Glycol,
Glucono Delta Lactone, Glycerin,

Histidine
Hydroxethylc-Cellulose, Magnesium Stearate, Methylparaben,
Sodium Hydroxide, Sorbic Acid, Steric Acid, Water.
     Sources:  U.S. Library of Medicine DailyMed and National Drug Codes List

NO MANUFACTURING LICENSE HAS BEEN ISSUED FOR TETRA STEM

Phillips Company's FDA Registered Pharma Products

Along with Steven J. Keough, Dr. Phillips is a named inventor of the patent-pending "Topical Drug Delivery System with Dual Carriers" on which Viabecline is based.
This invention is Published under two US Patent Application Numbers: 
US 20130190274  A1 and US 20120070390 A1 and through the WIPO. The Applicant was Pharmacline.


Dr. Phillips has retained a small-batch license (<20,000 Units) for Diabecline.  Thru Pharma LLC owns the Diabecline Trademark.

Steven J. Keough, the CEO of Thru Pharma LLC dba Dakota Life Sciences (now merged with Kasten OTC:PK KAST)  has confirmed their intention to protect
their patent-pending technology.  Dakota Life Sciences is engaged in developing
innovative health products utilizing Site Specific Penetration Technology SSPT™ technologies.
These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony™ OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™
RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as other valuable life sciences technologies.


"We believe in the core technology, and have solid plans to use it going forward. We did a voluntary recall in 2014 for the Diabecline branded antibiotic swab
because the formulation was causing deterioration of the swab tip. We will not have that configuration going forward, but will be using and protecting the technology."
--Steven J. Keough via email to shareholder March 5, 2017 -
Post 13474


In describing their use of this jointly-owned patent-pending invention, Keough's entities use their trademarked term
"Site Specific Penetration Technology™" and Otiko references his use of the Phillips/Keough patent as "proprietary innovative transdermal delivery system."


Two USPTO provisional application numbers were first shared by Otiko on March 20, 2017  for "two patents pending" (an inaccurate term).  See IP table below.
Provisionals establish an early filing date but do not mature into an issued patent unless the provisional is followed up with a patent application within a year.
While Dr. Otiko has referenced patent applications that have been submitted since 2014, no record of any applications show in a search of the USPTO Pair System.


"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

 
INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
 PATENTS TRADEMARKS
NAME NUMBER NOTES NAME NUMBER STATUS
2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
 
WAYBACK MACHINE CRAWL DATA
These are website capture dates, not the date content was updated.
CRAWL DATE LEAD PRODUCT ANNOUNCED ON WEBSITE ANNUAL SALES ANNUAL NET INCOME/LOSS WEBSITE COPYRIGHT YEAR
05/31/14 ViaDerma's proprietary transdermal delivery system     2014
10/18/14 ViaDerma's proprietary transdermal delivery system 130,859 (2014) -6,473,732 (2014) 2014
02/18/15 TetraStem     2014
04/11/15 TetraStem     2014
09/26/15 TetraStem 191,777 (2015) 27,121 (2015) 2014
01/11/16 TetraStem     2014
03/02/16 TetraStem     2014
03/04/16 TetraStem     2014
03/26/16 TetraStem     2014
05/17/16 TetraStem     2014
10/06/16 Diabecline     2014
02/10/17 Diabecline     2017
 
VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name Owner Registered Otiko's Role
BIOGENX
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
TBD
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
TBD CA
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.
 

RECENT NEWS

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes


02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results


01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017


12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VDRM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#18338   Agree bosman 03/29/17 09:19:44 AM
#18144  Sticky Note 2dollarbill Sunday, 03/26/17 01:59:16 PM whatarush12 03/28/17 09:49:16 AM
#17954  Sticky Note People believe whatever is most advantageous to them. CO422 03/26/17 03:38:25 PM
#14800  Sticky Note ViaDerma = $$'s coming this year! Here's all whatarush12 03/12/17 09:59:04 PM
#14176  Sticky Note NEWS FOR VDRM!! HIRES EXPERIENCED PRODUCT EXPERT Tradingtrader01 03/08/17 07:03:10 PM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#18337   Regardless of speculation over the price, the fact Maybe1day 03/29/17 08:33:06 AM
#18335   Without dilution the stock would be trading at bosman 03/29/17 07:59:01 AM
#18334   http://microcapspot.com/viaderma-inc-otcmktsvdrm-continues-trend-higher-new-deve whatarush12 03/29/17 07:37:54 AM
#18332   VDRM at 038 on the ask. Sherlockstock 03/29/17 07:27:16 AM
#18331   Great observation Golden. Today should be an interesting Hawk-02 03/29/17 03:26:47 AM
#18330   Bosman should have been more specific. While 19.68m hub2011 03/29/17 02:31:51 AM
#18328   Dilution from 200M to 220M happened between .01 Maybe1day 03/29/17 01:14:33 AM
#18327   Yes on dilution. Float grew by ~ 230M Neptune 03/29/17 01:07:42 AM
#18326   Actually going to side with Neptune. I Kingsolomonspoolz 03/29/17 12:44:06 AM
#18325   This is what the charts look like when Maybe1day 03/29/17 12:34:19 AM
#18324   Is dilution a concern here? Note that 99% pennyFreedom 03/29/17 12:33:52 AM
#18323   Such a beautiful chart. Classic stair stepping. pennyFreedom 03/29/17 12:21:47 AM
#18322   Sure, plenty of reasons, and plenty of opinions, Neptune 03/28/17 11:17:55 PM
#18321   If they ever want or need more financing, cwhockey31 03/28/17 10:36:55 PM
#18320   Wrong answer. This public company chose to be Neptune 03/28/17 10:33:15 PM
#18319   Because they are a "public" company hghscurry 03/28/17 10:23:45 PM
#18318   Why would they be "required" to be audited? Neptune 03/28/17 10:23:01 PM
#18317   The volume today is 19.68M. Your breakdown Swingtrader 03/28/17 10:14:17 PM
#18316   The FDA and VIABECLINE & TETRASTEM Uses 2dollarbill 03/28/17 10:13:58 PM
#18315   Why won't they likely have their financials audited? cwhockey31 03/28/17 10:11:19 PM
#18314   NOV 2016 Article & Link - Viabecline Results 2dollarbill 03/28/17 10:10:45 PM
#18313   2017 Article-Paraplegic walks after Tetratsem & stem cell treatment 2dollarbill 03/28/17 10:07:39 PM
#18312   The article is from 2016. Neptune 03/28/17 09:52:29 PM
#18311   Added 300k today.. ecstatic w/ my entries.. assuming Farmmarket1 03/28/17 09:44:57 PM
#18310   How high you think this goes in the GoldenDD 03/28/17 09:22:55 PM
#18309   I dont remember seeing this article in this hghscurry 03/28/17 09:03:24 PM
#18308   19.6 million shares, each both purchased and sold $VDRM Cheds 03/28/17 08:32:24 PM
#18307   Over 11 million shares sold little over 7 bosman 03/28/17 07:56:17 PM
#18306   Classic paint job bosman 03/28/17 07:52:49 PM
#18305   $VDRM - daily chart update - Target entry Cheds 03/28/17 07:41:21 PM
#18304   ViaDerma doesn't audit financials...never have and likely never will. Neptune 03/28/17 07:40:50 PM
#18303   VDRM PE Ratios $1.00 to $5.00 targets 2dollarbill 03/28/17 07:28:30 PM
#18302   VDRM PE Ratios - not destined to be 2dollarbill 03/28/17 07:20:41 PM
#18300   With proper auditing they should be able to jim992 03/28/17 06:20:30 PM
#18298   Based on the chart I see a 'W' GoldenDD 03/28/17 06:18:48 PM
#18297   You are welcome good sir! jim992 03/28/17 06:17:46 PM
#18296   Is it TRUE that even if these expected WatchTheMoneyGrow 03/28/17 06:16:12 PM
#18295   Very interesting, thanks! GoldenDD 03/28/17 06:15:02 PM
#18293   Found a nice album of DFCON 2017 pics: jim992 03/28/17 06:01:24 PM
#18292   Debating adding more or staying firm chico2663 03/28/17 05:15:59 PM
#18289  Restored I just got rid of this snake oil Prindle16 03/28/17 04:55:51 PM
#18288   This could go absolutely anywhere tomorrow. The GreenBrickRoad 03/28/17 04:54:44 PM
#18287   thats true but i rather pr once in tganz-banker 03/28/17 04:47:30 PM
#18285   Yeah I was under the impression that a Maybe1day 03/28/17 04:39:14 PM
#18284  Restored Now to get off my high horse it Dinduit 03/28/17 04:35:54 PM
#18282   It isn't a dead cat - when people BennyKrueger 03/28/17 04:29:44 PM
#18281   It would be nice to see a PR BennyKrueger 03/28/17 04:20:25 PM
#18280   not great of a day but i will tganz-banker 03/28/17 04:03:30 PM
#18279   Green Redfury000 03/28/17 04:01:25 PM
PostSubject